Bortezomib-d8

Cat. No.: IBDI-437798

Bortezomib-d8 is the deuterium labeled Bortezomib. Bortezomib (PS-341) is a reversible and selective proteasome inhibitor, and potently inhibits 20S proteasome (Ki=0.6 nM) by targeting a threonine residue. Bortezomib disrupts the cell cycle, induces apoptosis, and inhibits NF-κB. Bortezomib is the first proteasome inhibitor anticancer agent. Anti-cancer activity.

Product Details

Target	Proteasome | NF-κB | Apoptosis | Autophagy
Molecular Weight	392.29
Appearance	Solid
Synonyms	PS-341-d8, LDP-341-d8, NSC 681239-d8
Purity	≥98.0%

Storage & Handling

Shipping	Room temperature in continental US. May vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Regulatory Status	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use.